Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Biogen’s stock increased by 1% on Thursday following a positive opinion from Europe’s pharmaceutical regulator regarding their Alzheimer’s disease drug developed with Eisai. This decision reversed a previous ruling that had initially denied approval for the drug, indicating a positive shift in the regulatory landscape for the medication. The news of the favorable opinion boosted investor confidence and contributed to the rise in Biogen’s stock value.

Full Article